Hodgkin Disease/Lymphoma Clinical Practice Guidelines

Publisher Website
Google Scholar
Abstract
Cure rates for Hodgkin disease/lymphoma have increased to such an extent that the overriding treatment considerations often relate to long-term toxicity, especially for patients with early- or intermediate-stage disease. Current management programs are based on comprehensive clinical staging followed by combined modality therapy for patients with favorable and intermediate prognosis, or chemotherapy alone for patients with advanced disease. Relapse is uncommon, but secondary management with peripheral stem cell transplantation may be effective. The excellent prognosis for these patients mandates careful long-term follow-up to detect late treatment effects. For the most recent version of the guidelines, please visit NCCN.org

This publication has 0 references indexed in Scilit: